Obicetrapib + Ezetimibe for Coronary Artery Disease

(REMBRANDT Trial)

Overseen By Claudia Forkel

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: NewAmsterdam Pharma

Must be taking: Lipid-modifying therapy

Disqualifiers: Diabetes, Liver disease, others

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 18 months

300 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination of two medications, obicetrapib and ezetimibe, to determine if they can reduce heart disease by shrinking plaque and reducing inflammation in the arteries. It targets individuals with coronary artery disease who have not successfully lowered their cholesterol with current medication. Participants should have high cholesterol that isn’t well-controlled and non-calcified plaque in their major heart arteries. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking treatment advancements.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop your current medications, but it mentions that participants should be on their maximum tolerated lipid-modifying therapy. This suggests you may need to continue your current lipid-modifying medications.

Is there any evidence suggesting that this trial's treatment is likely to be safe?

Research has shown that the combination of obicetrapib and ezetimibe is generally safe for patients. In earlier studies, most participants did not experience serious side effects. A few reported mild issues like headaches or stomach upset, but these were uncommon.

Obicetrapib is a new drug that helps lower bad cholesterol, while ezetimibe is already FDA-approved to reduce cholesterol levels. Together, they work more effectively to lower cholesterol.

Safety results from other studies indicate that this combination can safely help manage cholesterol for those needing additional support beyond their usual medication. Although no treatment is without risks, current evidence suggests this combination is safe for most people. Always consult your doctor to determine if this option is suitable for you. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Researchers are excited about the combination of Obicetrapib and Ezetimibe for coronary artery disease because it offers a novel approach to lowering cholesterol. While standard treatments like statins reduce cholesterol by blocking its production in the liver, Obicetrapib works by inhibiting a protein called CETP, which can increase "good" HDL cholesterol and lower "bad" LDL cholesterol. Ezetimibe, on the other hand, reduces cholesterol absorption in the intestines. By combining these two mechanisms, this treatment has the potential to more effectively manage cholesterol levels, especially for patients who don't respond well to statins alone.

What evidence suggests that this treatment might be an effective treatment for coronary artery disease?

This trial will evaluate the combination of obicetrapib and ezetimibe to assess its effectiveness in lowering LDL cholesterol, often known as "bad" cholesterol. Research has shown that this combination can lead to an average LDL reduction of 48.6%. Lowering LDL cholesterol is important because it can help reduce the risk of heart diseases, such as coronary artery disease. Obicetrapib reduces cholesterol, while ezetimibe prevents cholesterol absorption in the gut. Together, they tackle cholesterol from different angles, providing a strong approach to managing high cholesterol. ^{1 2 3 5 6}

Are You a Good Fit for This Trial?

This trial is for adults with high-risk heart-related artery disease who aren't responding well to their current cholesterol-lowering treatments. They should have a certain amount of plaque in their arteries, a body mass index between 18-40, proper kidney function, and LDL cholesterol over 70mg/dL.

Inclusion Criteria

My LDL cholesterol is above 70 mg/dL.

My kidney function is normal or only mildly reduced.

My heart's arteries have significant plaque buildup.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive obicetrapib 10 mg + ezetimibe 10 mg FDC daily or placebo for 18 months

18 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4-8 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Obicetrapib/Ezetimibe

Trial Overview

The study tests if taking obicetrapib plus ezetimibe daily can change the characteristics of coronary plaque and inflammation. This is measured using advanced heart scans (CCTA). Participants are randomly chosen to either receive this combination or a placebo without knowing which one they get.

How Is the Trial Designed?

Group I: Obicetrapib/Ezetimibe Experimental Treatment 1 Intervention

obicetrapib 10 mg + ezetimibe 10 mg FDC daily

Group II: Placebo Placebo Group 1 Intervention

Placebo on top of baseline lipid modifying therapy

Who Is Running the Clinical Trial?

NewAmsterdam Pharma

Lead Sponsor

Trials

17

Recruited

13,900+

Published Research Related to This Trial

Coronary artery disease (CAD) is a leading cause of illness and death in the U.S., and its diagnosis involves a combination of clinical exams, noninvasive techniques, and catheterization.

Effective treatment options for CAD include a range of medications like aspirin and beta-blockers, as well as procedures like angioplasty and bypass surgery, with an emphasis on personalized care based on recent clinical trial findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Diagnosis and management of coronary artery disease. Blanchard, A., Pfeffer, MA.[2019]

In a study of 299 patients undergoing elective PCI or NSTEMI, administering a P2Y12 inhibitor only after coronary angiography resulted in a low incidence of major ischemic events (8.5%) and no cases of definite stent thrombosis within 30 days.

The approach was associated with a clinically relevant bleeding rate of 5.4%, suggesting that this 'on-the-table' loading strategy is both safe and effective in real-world settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of Percutaneous Coronary Intervention Without P2Y12 Inhibitor Pretreatment From a Cohort of Unselected Patients. Lattuca, B., Belardi, D., Demattei, C., et al.[2018]

In a randomized, double-blind, placebo-controlled trial involving 120 dyslipidaemic patients, the CETP inhibitor obicetrapib significantly reduced LDL cholesterol levels by up to 51% over 8 weeks when added to high-intensity statin therapy.

Obicetrapib also decreased apolipoprotein B and non-HDL cholesterol levels while increasing HDL cholesterol by up to 165%, demonstrating its potential as an effective treatment for high-cardiovascular-risk patients with an acceptable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nicholls, SJ., Ditmarsch, M., Kastelein, JJ., et al.[2022]

Percutaneous coronary intervention (PCI) has significantly improved in safety and efficacy over the past two decades due to advancements like drug-eluting stents and better pharmacological support, enhancing procedural success and long-term outcomes.

Despite these improvements, there is a growing concern about increased mortality associated with drug-eluting stents, prompting physicians to follow FDA guidelines until further studies clarify this risk.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Percutaneous coronary intervention: the story so far. Martinez-Ojeda, J., Martinez-Toro, J.[2010]

Dual antiplatelet therapy with aspirin and clopidogrel is commonly used during percutaneous coronary intervention (PCI) to prevent complications, but individual responses can vary due to genetic factors and other influences.

Newer oral antiplatelet agents like prasugrel and ticagrelor offer greater effectiveness in reducing ischaemic events but are associated with a higher risk of bleeding, highlighting the need for careful risk assessment when selecting treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Wong, YW., Prakash, R., Chew, DP.[2018]

In a study of 109 patients with acute coronary syndrome who underwent percutaneous coronary intervention, both ticagrelor and clopidogrel showed comparable effectiveness in preventing ischemic events, with no significant differences in stent thrombosis rates.

However, ticagrelor was associated with a higher frequency of minor bleeding compared to clopidogrel, which demonstrated better hemorrhagic safety, particularly in terms of fatal bleeding incidents.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice]. Korotaeva, ES., Koroleva, LY., Kovaleva, GV., et al.[2019]

In a phase 2 trial with 97 patients, the combination of obicetrapib and ezetimibe significantly reduced LDL cholesterol levels by 63.4% compared to only 6.35% in the placebo group, demonstrating strong lipid-altering efficacy.

Obicetrapib was well tolerated with no safety issues reported, indicating that it is a safe adjunct therapy when added to high-intensity statin treatment for patients with elevated LDL cholesterol.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. Ballantyne, CM., Ditmarsch, M., Kastelein, JJ., et al.[2023]

In a phase IV clinical trial involving patients with atherosclerotic cardiovascular disease (ASCVD), the combination therapy of moderate-intensity rosuvastatin and ezetimibe significantly reduced LDL cholesterol levels more than high-intensity rosuvastatin alone after 12 and 24 weeks.

The combination therapy also resulted in a higher percentage of patients reaching the target LDL-C level of ≤70 mg/dL, while maintaining a similar safety profile with no significant increase in adverse events compared to the monotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea. Choi, H., Kang, SH., Jeong, SW., et al.[2023]

In a study of 144 patients with coronary artery disease, coadministering ezetimibe with simvastatin led to a significant additional reduction in LDL cholesterol levels by 17.6% compared to simvastatin alone after 6 weeks.

The combination therapy also resulted in more patients reaching the target LDL cholesterol levels set by the National Cholesterol Education Program (70% vs. 33% for simvastatin alone), and it was well tolerated with a safety profile similar to simvastatin monotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. Zubaid, M., Shakir, DK., Bazargani, N., et al.[2015]

In a study of 827 patients with primary hypercholesterolemia, ezetimibe 10 mg/day significantly reduced low-density lipoprotein cholesterol (LDL-C) by an average of 17.7% compared to a 0.8% increase with placebo, demonstrating its efficacy in lowering cholesterol levels.

Ezetimibe was well tolerated and had a safety profile similar to placebo, without affecting lipid-soluble vitamins or cortisol production, suggesting it is a safe option for managing cholesterol levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Knopp, RH., Gitter, H., Truitt, T., et al.[2019]

Citations

1.

thelancet.com

thelancet.com/journals/lancet/article/PIIS0140-6736(25)00721-4/abstract

Fixed-dose combination of obicetrapib and ezetimibe for ...

The aim of this study was to evaluate the LDL cholesterol-lowering efficacy of a fixed-dose combination (FDC) of obicetrapib, a CETP inhibitor, and ezetimibe.

2.

sciencedirect.com

sciencedirect.com/science/article/abs/pii/S0002870325002212

A phase 3 study to evaluate the effect of obicetrapib ...

REMBRANDT is a placebo-controlled, double-blind, randomized trial designed to assess the efficacy of obicetrapib and ezetimibe FDC on coronary plaque burden.

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06005597

NCT06005597 | Study of Obicetrapib & Ezetimibe Fixed ...

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or ...

4.

ir.newamsterdampharma.com

ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-announces-positive-topline-data-pivotal-0

NewAmsterdam Pharma

The TANDEM trial met all co-primary endpoints, including the obicetrapib-ezetimibe fixed dose combination achieving an LS mean reduction of 48.6%.

5.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12528909/

Efficacy and safety of obicetrapib in patients with dyslipidemia

Obicetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor with promising lipid-lowering effects.

6.

nejm.org

nejm.org/doi/pdf/10.1056/NEJMoa2415820

Safety and Efficacy of Obicetrapib in Patients at High ...

7-9 In most patients at very high risk for cardiovascular events, combination therapy is needed to achieve an LDL cholesterol level of less than ...